Reviews/Targeted Therapy Prostate Cancer/Olaparib radiographic progression-free survival in homologous recombination repair-mutant metastatic castration-resistant prostate cancer
PARP · PC-PARP-01 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
The claim says the drug olaparib delays the point at which prostate cancer is seen to grow on scans, better than two standard hormone treatments, in men whose tumours carry faults in DNA-repair genes, especially BRCA1/2. The corpus shows this comes from a single large, properly randomised trial called PROfound [1], which also reported that these men lived longer on olaparib (about 19 versus 15 months) [1]. A follow-on analysis gives the hard scan-progression number for the BRCA and ATM group, a risk reduction expressed as a hazard ratio of 0.34 [3], and a brief later report confirms the benefit specifically in BRCA1/2 patients [2]. Other olaparib studies in the corpus [5][15] show the drug works but did not compare it against the hormone treatments, so they cannot confirm the head-to-head claim. The panel landed where it did because the comparison is directly supported by one strong trial with a concrete in-corpus number, while everything rests on that one trial and one of the confirming reports is very thin.
The corpus demonstrates that in the randomised, open-label phase 3 PROfound trial olaparib produced significantly longer imaging-based progression-free survival than physician's-choice enzalutamide or abiraterone in HRR-altered mCRPC [1]. The BRCA/ATM primary population carries a radiographic progression-free survival hazard ratio of 0.34 (95% CI 0.25-0.47), with the ctDNA-identified subgroup showing 7.4 versus 3.5 months and a hazard ratio of 0.33 [3]. A later report states olaparib improved PFS and OS across BRCA1/2mut subgroups in the same trial [2]. Overall survival in Cohort A was 19.1 versus 14.7 months (HR 0.69) [1], concordant with the progression-free benefit. Single-arm olaparib studies corroborate activity in BRCA-mutated disease (median PFS 15.8 months) [15] and DDR-aberrant disease [5] but carry no enzalutamide or abiraterone comparator. The contested point: The division is not over direction but over verbatim support and independence: the comparative radiographic progression-free survival hazard ratio appears only as a secondary statement inside an exploratory ctDNA paper [3], while [1] references the rPFS advantage without numbers, so the primary overall-population figure is not stated verbatim in the corpus. All comparative evidence derives from the single PROfound trial, and the BRCA1/2 confirmation [2] is a one-sentence report with no N, confidence interval or methodology.
All 15 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Targeted Therapy Prostate Cancer, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
rPFS is a radiographic surrogate endpoint; the claim rests on it, though [1] shows the OS co-primary moved in the same direction (HR 0.69), limiting the surrogate concern.
The comparative rPFS hazard ratio appears only as a secondary statement inside an exploratory ctDNA paper [3]; [1] references the rPFS result without numbers, so the primary overall-population rPFS figure is not stated verbatim in the corpus.
Where it remains uncertain. The comparative rPFS hazard ratio is stated only inside an exploratory ctDNA analysis [3] and the BRCA1/2 confirmation is a single sentence without N or confidence interval [2]; all comparative evidence comes from one trial, with no independent replication [5][15].
Aleatory
The ctDNA subgroup is a small slice (73 olaparib, 38 control) of Cohort A, so its point estimates carry sampling noise even though they track the ITT population [3].
Epistemic
rPFS is a radiographic surrogate; the claim rests on it, though the concordant overall-survival direction in Cohort A (HR 0.69) limits the concern [1].
The load-bearing papers from a corpus of 15, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Establishes, from the pivotal PROfound trial, that olaparib produced a significantly longer rPFS than enzalutamide/abiraterone in HRR-altered mCRPC.
“We previously reported that olaparib led to significantly longer imaging-based progression-free survival than the physician's choice of enzalutamide or abiraterone among men with metastatic castration-resistant prostate cancer who had qualifying alterations in homologous recombination repair genes and whose disease had progressed during previous treatment with a next-generation hormonal agent.”
Panel auditInternal validity: high · scope of inference: Men with mCRPC and HRR gene alterations progressing after a next-generation hormonal agent; this report's own endpoint is OS, with rPFS referenced from the prior report.Key limitations: rPFS numbers not in this abstract (restatement only) · open-label · substantial crossover to olaparib
Confirms the benefit specifically in the BRCA1/2-mutant subgroup, supporting the claim's 'particularly BRCA1/2' qualifier.
“Olaparib improved PFS and OS across subgroups of BRCA1/2mut #prostatecancer patients in the PROFOUND phase III trial.”
Panel auditInternal validity: not assessable from abstract · scope of inference: BRCA1/2-mutant mCRPC patients within the PROfound phase 3 trial.Key limitations: one-sentence abstract · no numbers · comparator arm not named · significance not stated
Supplies the comparative rPFS hazard ratio for the BRCA/ATM primary population (Cohort A ITT HR 0.34), the hard number underpinning the significance and the BRCA emphasis.
“rPFS was longer in the olaparib group versus control [median 7.4 vs. 3.5 months; hazard ratio (HR), 0.33; 95% confidence interval (CI), 0.21-0.53; nominal P < 0.0001], which is consistent with Cohort A ITT population (HR, 0.34; 95% CI, 0.25-0.47).”
Panel auditInternal validity: high · scope of inference: mCRPC patients with BRCA/ATM alterations (Cohort A), with a focus on ctDNA-based identification of eligible patients.Key limitations: exploratory/retrospective ctDNA subgroup · nominal P value · Cohort A only (BRCA/ATM)
No comparison of olaparib against enzalutamide or abiraterone is made; the trial compares two olaparib doses using a composite response endpoint.
Panel auditInternal validity: medium · scope of inference: mCRPC patients with DDR gene aberrations previously treated with taxane chemotherapy, assessing olaparib activity by dose.Key limitations: no enz/abi comparator · composite response not rPFS vs control · two-dose comparison only
4 of 15 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
A pivotal phase 3 RCT directly supports the comparative rPFS benefit with an in-corpus hazard ratio, held just inside Established by single-trial dependence and the thinness of the BRCA1/2 confirmatory report.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Verbatim overall-population primary rPFS result. The corpus lacks the primary intention-to-treat rPFS hazard ratio for the full PROfound population; only the Cohort A figure appears, and only inside an exploratory paper [3]. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: Include the primary PROfound rPFS publication reporting the overall-population and Cohort A/B rPFS hazard ratios and confidence intervals.
Open question: What is the primary intention-to-treat radiographic progression-free survival hazard ratio for the full HRR-altered PROfound population? Why it is still open: Only the Cohort A estimate (HR 0.34) is in the corpus, reported within an exploratory ctDNA paper [3]; [1] references rPFS without a number.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 26 Oct 2026 · protocol v0.19